T 1708/18 (PCSK9 variants/BRISTOL-MYERS SQUIBB) du 14.02.2022
- Identifiant européen de la jurisprudence
- ECLI:EP:BA:2022:T170818.20220214
- Date de la décision
- 14 février 2022
- Numéro de l'affaire
- T 1708/18
- Requête en révision de
- -
- Numéro de la demande
- 07873840.8
- Classe de la CIB
- A61K 38/00C12N 9/64
- Langue de la procédure
- Anglais
- Distribution
- Non distribuées (D)
- Téléchargement
- Décision en anglais
- Versions JO
- Aucun lien JO trouvé
- Autres décisions pour cet affaire
- -
- Résumés pour cette décision
- Résumé de EPC2000 Art 117
- Titre de la demande
- Polynucleotides encoding novel PCSK9 variants
- Nom du demandeur
- Bristol-Myers Squibb Company
- Nom de l'opposant
- Regeneron Pharmaceuticals, Inc.
Sanofi
Pfizer Inc. - Chambre
- 3.3.04
- Sommaire
- -
- Dispositions juridiques pertinentes
- European Patent Convention Art 54
- Mots-clés
- Novelty - (no)
- Exergue
- 1. The issue of which standard of disclosure applies when assessing the legal question of novelty and the issue of which standard of proof applies when assessing evidence and factual questions are distinct and unrelated. The fact that the standard of disclosure required for a finding of lack of novelty (or for allowing an amendment to the application under Article 123(2) EPC) is the standard of a direct and unambiguous disclosure is immaterial for the question of what standard of proof applies when considering evidence and factual issues in the context of novelty (or inventive step) (see point 16).
2. The standard of proof generally applied at the EPO for deciding on an issue of fact is the balance of probabilities. According to this standard, the EPO must base its decisions on statements of fact which, based on the available evidence, are more likely than not to be true. This standard also applies when examining factual issues in the context of novelty (see point 14). - Affaires citantes
- T 0358/22
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.